UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 10-Qx
QUARTERLY REPORT UNDER TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2012ORo
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934Commission file number 333-123134








INTERNATIONAL GOLD CORP.


(Exact name of registrant as specified in its charter)





NEVADA


(State or other jurisdiction of incorporation or organization)





1111 West Georgia Street, Suite 1720


Vancouver, British Columbia


Canada V6E 4M8


(Address of principal executive offices, including zip code.)





(604) 687-0760


(telephone number, including area code)





Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days.  YESxNOo





Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer, “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.





Large Accelerated Filer
o
Accelerated Filer
oNon-accelerated Filer
o
Smaller Reporting Company
x





Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.  YESxNOo





State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: 9,604,000 as of August 13, 2012.





1








TABLE OF CONTENTS





PagePART I - FINANCIAL INFORMATIONItem 1.       Financial Statements

3Balance Sheets as of June 30, 2012 (unaudited) and December 31, 2011

4Statements of Operations for the Six Months ended June 30, 2012 and 2011 (unaudited)

5Statements of Cash Flows for the Six Months ended June 30, 2012 and 2011  (unaudited)

6Notes to Financial Statements (unaudited)

7Item 2.       Management’s Discussion and Analysis Of Financial Condition and Results of Operations

14Item 3.       Quantitative and Qualitative Disclosures About Market Risk

21Item 4.       Controls and Procedures

21PART II - OTHER INFORMATIONItem 1A.    Risk Factors

21Item 2.       Registered Sales of Equity Securities and Use of Proceeds

22Item 6.       Exhibits

22SIGNATURES

22




















2





PART I – FINANCIAL INFORMATION





ITEM 1.  FINANCIAL STATEMENTS.















































INTERNATIONAL GOLD CORP.








INTERIM FINANCIAL STATEMENTS





FOR THE SIX MONTHS ENDED JUNE 30, 2012 AND 2011


(Unaudited)


(Stated in U.S. Dollars)










































































3




INTERNATIONAL GOLD CORP.
 
 INTERIM BALANCE SHEETS
 (Stated in U.S. Dollars)
 
 JUNE 30


DECEMBER 312012


2011(Unaudited)ASSETSCurrentCash

$
105


$
759Amounts receivable


21,606



9,144$
21,711


$
9,903LIABILITIESCurrentAccounts payable and accrued liabilities

$
150,879


$
117,680Loans payable


94,652



112,289Amounts due to related party


25,482



41,974Promissory notes due to related party


6,808



6,579277,821



278,522Contractual Obligations And Commitments (Note 6)Subsequent Events (Note 8)STOCKHOLDERS’ DEFICIENCYCapital StockAuthorized:100,000,000 voting common shares with a par value of $0.00001 per shareIssued:6,250,000 common shares at June 30, 2012 and December 31, 2011


63



63Additional Paid-In Capital


165,487



165,487Shares To Be Issued


146,700



10,000Accumulated Deficit


(568,360
)


(444,169
)(256,110
)


(268,619
)$
21,711


$
9,903





The accompanying condensed notes are an integral part of these interim financial statements.





4





INTERNATIONAL GOLD CORP.





INTERIM STATEMENTS OF OPERATIONS


(Unaudited)


(Stated in U.S. Dollars)











THREE MONTHS ENDED


SIX MONTHS ENDEDJUNE 30


JUNE 302012


2011


2012


2011Revenue

$
-


$
-


$
-


$
-ExpensesConsulting services


22,500



-



45,000



-Corporate support services


8,995



-



19,995



8,917Interest, bank and finance charges


4,805



10,746



10,948



11,499Office, foreign exchange and sundry


(685
)


3,274



4,088



6,545Professional fees


28,853



23,608



38,468



23,609Transfer and filing fees


4,750



2,350



5,692



3,50869,218



39,978



124,191



54,078Net Loss For The Period

$
(69,218
)

$
(39,978
)

$
(124,191
)

$
(54,078
)Basic And Diluted Loss Per Common Share

$
(0.01
)

$
(0.01
)

$
(0.02
)

$
(0.01
)Weighted Average Number Of Common  Shares Outstanding


6,250,000



6,035,714



6,250,000



6,017,956


















































The accompanying condensed notes are an integral part of these interim financial statements.








5





INTERNATIONAL GOLD CORP.





INTERIM STATEMENTS OF CASH FLOWS


(Unaudited)


(Stated in U.S. Dollars)











SIX MONTHS ENDEDJUNE 302012


2011Cash Provided By (Used In)Operating ActivitiesNet loss for the period

$
(124,191
)

$
(54,078
)Adjustments to reconcile net loss to net cash used in operating activities:Accrued interest payable


4,720



1,502Non-cash finance fees


-



6,250Loss on foreign exchange


372



4,516Net changes in non-cash operating working capital items:Amounts receivable


(12,462
)


2,385Accounts payable and accrued liabilities


33,199



16,982(98,362
)


(22,443
)Investing ActivitiesMineral property deposit


-



(75,000
)-



(75,000
)Financing ActivitiesIssuance of common stock subscriptions


114,200



-Advances from (repayments to) related parties


(16,492
)


5,400Advances from loans payable


-



90,00097,708



95,400Net Decrease In Cash


(654
)


(2,043
)Cash, Beginning Of Period


759



1,981Cash, End Of Period

$
105


$
(62
)Supplemental Disclosure Of Cash Flow InformationCash paid during the period for:Interest

$
-


$
-Income taxes

$
-


$
-Non-cash Financing ActivityCommon shares issued as financing fee

$
-


$
6,250





The accompanying condensed notes are an integral part of these interim financial statements.














6


INTERNATIONAL GOLD CORP.





CONDENSED NOTES TO INTERIM FINANCIAL STATEMENTS





FOR THE SIX MONTHS ENDED JUNE 30, 2012 AND 2011


(Unaudited)


(Stated in U.S. Dollars)








1.
BASIS OF PRESENTATION AND NATURE OF OPERATIONS





Organization





International Gold Corp. (“the Company”) was incorporated in the State of Nevada, U.S.A., on December 9, 2004.  The Company’s principal executive offices are located in Vancouver, British Columbia, Canada.  The Company was originally formed for the purpose of acquiring exploration stage natural resource properties. The Company currently has no properties, is not conducting any exploration work and is currently not in the “exploration stage”.  The Company has not yet realized any revenues from its operations.





Going Concern





The accompanying financial statements have been prepared assuming the Company will continue as a going concern.





The future of the Company is dependent upon its ability to establish a business and to obtain new financing to execute a business plan. As shown in the accompanying financial statements, the Company has incurred accumulated losses of $568,360 for the period from December 9, 2004 (inception) to June 30, 2012, and has had no revenue.  There is no assurance that management’s plans to seek additional capital through private placements of its common stock will be realized, and these factors cast substantial doubt upon the use of the going concern assumption. These financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence.





Basis of Presentation





The unaudited financial information furnished herein reflects all adjustments which, in the opinion of management, are necessary to fairly state the Company’s financial position and the results of its operations for the periods presented.  These second quarter financial statements should be read in conjunction with the Company’s financial statements and notes thereto included in the Company’s report on Form 10-K for the year ended December 31, 2011.  The Company assumes that the users of the interim financial information herein have read, or have access to, the audited financial statements for the preceding fiscal year, and that the adequacy of additional disclosure needed for a fair presentation may be determined in that context.  Accordingly, footnote disclosure, which would substantially duplicate the disclosure contained in the Company’s financial statements for the fiscal year ended December 31, 2011, has been omitted.  The results of operations for the six month period ended June 30, 2012 are not necessarily indicative of results for the entire year ending December 31, 2012.














7





INTERNATIONAL GOLD CORP.





CONDENSED NOTES TO INTERIM FINANCIAL STATEMENTS





FOR THE SIX MONTHS ENDED JUNE 30, 2012 AND 2011


(Unaudited)


(Stated in U.S. Dollars)








2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES





The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”).  Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements for a period necessarily involves the use of estimates which have been made using careful judgment.  All dollar amounts are in U.S. dollars unless otherwise noted.





The financial statements have, in management’s opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below:





a)
Exploration Stage Enterprise





The Company’s financial statements have been prepared using the accrual method of accounting and according to the provisions of Accounting Standards Codification (“ASC”) Topic 915, Development Stage Entities. To the end of the prior fiscal year, the Company had devoted substantially all of its efforts to acquiring and exploring mineral properties. It currently has no properties and no exploration program.





b)
Mineral Property Costs





Mineral property exploration costs were expensed as incurred. Mineral property acquisition costs were initially capitalized when incurred.  The Company assessed the carrying costs for impairment at each fiscal quarter end.  If it had been determined that a mineral property could be economically developed as a result of establishing proven and probable reserves, the costs then incurred to develop such property would be capitalized. Such costs would be amortized using the unit-of-production method over the estimated life of the probable reserve.  If mineral properties were subsequently abandoned or impaired, any capitalized costs would be charged to operations.





c)
Long-lived Assets





The Company currently has no long-lived assets. If it acquires any, the Company will test long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life.





Recoverability is assessed based on the carrying amount of the asset and its fair value which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.





d)
Asset Retirement Obligations





Asset retirement obligations, including environmental expenditures, that relate to current operations are charged to operations or capitalized as appropriate. Expenditures that relate to an existing condition caused by past operations, and which do not contribute to current or future revenue generation, are charged to operations. Liabilities are recorded when retirement obligations, including environmental assessments and/or remedial efforts, are probable, and the cost can be reasonably estimated.





8


INTERNATIONAL GOLD CORP.





CONDENSED NOTES TO INTERIM FINANCIAL STATEMENTS





FOR THE SIX MONTHS ENDED JUNE 30, 2012 AND 2011


(Unaudited)


(Stated in U.S. Dollars)











2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)





e)
Cash and Cash Equivalents





Cash consists of cash on deposit with high quality major financial institutions, and to date, the Company has not experienced losses on any of its balances.  The carrying amounts approximated fair market value due to the liquidity of these deposits.  For purposes of the balance sheet and statement of cash flows, the Company considers all highly liquid debt instruments purchased with maturity of 90 days or less to be cash equivalents.





f)
Foreign Currency Accounting





The Company’s functional currency is the U.S. dollar.  Head office financing and investing activities are generally in Canadian dollars. Transactions in Canadian currency are translated into U.S. dollars as follows:





i)
monetary items at the exchange rate prevailing at the balance sheet date;


ii)
non-monetary items at the historical exchange rate; and


iii)
revenue and expense items at the rate in effect of the date of transactions.





Gains and losses arising on the settlement of foreign currency denominated transactions or balances are recorded in the statements of operations.





g)
Fair Value of Financial Instruments





ASC Topic 820-10 establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value.  The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.


These tiers include:





§
Level 1 – defined as observable inputs such as quoted prices in active markets;


§
Level 2 – defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and


§
Level 3 – defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.





Cash consists of cash on deposit with a high quality major financial institution. The carrying cost approximates fair value due to the liquidity of these deposits.  The carrying amounts of other financial assets and liabilities comprising amounts receivable, loan receivable, accounts payable and accrued liabilities, loans payable and amounts due to related party, were reasonable approximations of their fair value.





h)
Use of Estimates and Assumptions





The preparation of financial statements, in conformity with United States generally accepted accounting principles, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures.  By their nature, these estimates are subject to measurement uncertainty and the effect on the financial statements of changes in such estimates in future periods could be significant.  Significant areas requiring management’s estimates and assumptions are determining the fair value of transactions involving common stock, valuation and impairment losses on mineral property acquisitions and values recorded for related party transactions.  Actual results may differ from the estimates.





9


INTERNATIONAL GOLD CORP.





CONDENSED NOTES TO INTERIM FINANCIAL STATEMENTS





FOR THE SIX MONTHS ENDED JUNE 30, 2012 AND 2011


(Unaudited)


(Stated in U.S. Dollars)











2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)





i)
Basic and Diluted Loss Per Share





The Company reports basic loss per share in accordance with ASC Topic 260, “Earnings Per Share”.  Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common stock outstanding during the period.  Diluted loss per share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. As the Company generated net losses in the period presented, the basic and diluted loss per share are the same, as any exercise of options or warrants would be anti-dilutive.





j)
Stock-based Compensation





The Company adopted ASC Topic 718, “Compensation – Stock Compensation”, which addresses the accounting for stock-based payment transactions in which an enterprise receives employee services in exchange for (a) equity instruments for the enterprise, or (b) liabilities that are based on the fair value of the enterprise’s equity instruments or that may be settled by the issuance of such equity instruments.  The Company uses the Black-Scholes option-pricing model to determine the fair-value of these transactions.  To June 30, 2012, the Company has not granted any stock options.





k)
Income Taxes





The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, Income Taxes.  This standard requires the use of an asset and liability approach for financial accounting and reporting on income taxes.  If it is more likely than not that some portion or all of a deferred tax asset will not be realized, a valuation allowance is recognized.





l)
Recent Accounting Pronouncements





From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date.  Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial statements upon adoption.








3.
CAPITAL STOCK





During the six months ended June 30, 2012: the Company received payments totaling $114,200 as subscriptions for 2,284,000 shares of its common stock, and loans totaling $22,500 Canadian were converted to a subscription for 450,000 shares of the Company’s common stock.





In July, 2012, the Company received payments totaling $15,000 as subscriptions for 300,000 shares of its common stock, and $6,000 of loan principal and interest was converted to a subscription for 120,000 shares of the Company’s common stock.





On July 24, 2012, the Company issued 3,354,000 shares of its common stock in return for shares to be issued totaling $146,700 as at June 30, 2012, together with the July, 2012 subscriptions totaling $21,000 as detailed immediately above.





On August 9, 2012, the Company received $50,000 as a subscription for 250,000 shares of its common stock. Those shares have not yet been issued.





The Company has no stock option plan, warrants or other dilutive securities.





10


INTERNATIONAL GOLD CORP.





CONDENSED NOTES TO INTERIM FINANCIAL STATEMENTS





FOR THE SIX MONTHS ENDED JUNE 30, 2012 AND 2011


(Unaudited)


(Stated in U.S. Dollars)











4.
LOANS PAYABLE





During the six months ended June 30, 2012:





·
Interest totaling $4,488 (2011 - $627) was accrued on loan amounts;


·
Loans totaling $22,500 Canadian were converted to a subscription for 450,000 shares of the Company’s common stock. Those shares were issued on July 24, 2012.








5.
RELATED PARTY TRANSACTIONS AND AMOUNTS DUE





Transactions with related parties were in the normal course of operations and have been valued in these financial statements at the exchange amount, which is the amount of consideration agreed to and established by the related parties.





a)
Amounts Due to Related Party





The Company was indebted at June 30, 2012 and December 31, 2011, for unsecured, non-interest bearing loans with no specific terms of repayment, totaling $25,482 and $41,974 respectively. The total amount was due to the sole director and officer of the Company and a company or companies controlled by this director.





Other amounts due to the above noted related party and included in accounts payable totaled $30,868 at June 30, 2012 and $35,049 at December 31, 2011.





b)
Promissory Notes Due to Related Party





The Company was indebted at June 30, 2012 for unsecured promissory notes due on demand, bearing interest at 8% per annum, totaling $6,808, including accrued interest (December 31, 2011 - $6,579).





The above amounts, including accrued interest of $968 (December 31, 2011: $736), were due to a company controlled by the sole director and officer of the Company.








6.
CONTRACTUAL OBLIGATIONS AND COMMITMENTS





A consulting agreement was executed by the Company for the provision of corporate compliance services, administrative services, and bookkeeping, dated for reference January 1, 2011. The agreement calls for a monthly fee of $3,000 (Canadian) plus applicable taxes. In recognition of the Company’s constrained financial condition, the consultant agreed to forego regular monthly fees in 2011 and accepted seven months’ fees to December 31, 2011 totaling $18,208. In the period ended June 30, 2012, regular monthly fees commenced which, together with a one-time payment of $2,000 in recognition of 2011 payments foregone, totaled $19,995. The agreement remains in effect until terminated by either party on one month’s notice. In the event that the Company terminates the agreement other than for cause, the Company is required to pay two months’ fees as a termination fee.





On February 21, 2012 a consulting agreement was fully executed between the Company and another company controlled by the sole director and officer of the Company, effective January 1, 2012 for a term of 48 months, whereby the other company has agreed to provide the services of its shareholder as the Company’s CEO, COO, CFO and Corporate Secretary.  As compensation, the Company is to pay $90,000 per annum, in equal monthly installments of $7,500, in arrears and plus applicable taxes.  The Company has also agreed to reimburse reasonable business and/or entertainment and automobile expenses during the duration of the consulting agreement. The agreement may be terminated by either party on thirty days’ notice. In the event that the agreement is terminated on a change of control of the Company or, other than for cause, the consultant is entitled to a severance payment equivalent to twelve months of fees.


11


INTERNATIONAL GOLD CORP.





CONDENSED NOTES TO INTERIM FINANCIAL STATEMENTS





FOR THE SIX MONTHS ENDED JUNE 30, 2012 AND 2011


(Unaudited)


(Stated in U.S. Dollars)











7.
FAIR VALUE OF ASSETS AND LIABILITIES





Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. U.S. GAAP requires that valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820-10 Fair Value Measurements also establishes a fair value hierarchy which prioritizes the valuation inputs into three broad levels. Based on the underlying inputs, each fair value measurement in its entirety is reported in one of the three levels. These levels are:





Level 1 - Valuation is based upon quoted prices for identical instruments traded in active markets. Level 1 assets and liabilities include debt and equity securities traded in an active exchange market, as well as U.S. Treasury securities.





Level 2 - Valuation is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.





Level 3 - Valuation is determined using model-based techniques with significant assumptions not observable in the market.





The following tables present information about the Company’s financial instruments that have been measured at fair value as of June 30, 2012 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair values:





LEVEL


HELD-FOR- TRADING


LOANS AND

RECEIVABLES/

AMORTIZED

COST


TOTAL

CARRYING

VALUE


FAIR VALUEFinancial assetsCash


1


$
105


$
-


$
105


$
105





LEVEL


OTHER

FINANCIAL

LIABILITIES


TOTAL

CARRYING

VALUE


FAIR VALUEFinancial liabilitiesLoans payable, including interest


2


$
94,652


$
94,652


$
94,652Promissory notes due to related party, including interest


2



6,808



6,808



6,808$
101,460


$
101,460


$
101,460





The carrying amount of level 1 and level 2 financial instruments approximates fair value because of the short maturity of the instruments.





The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no significant transfers between Level 1, Level 2, or Level 3 during the six month period ended June 30, 2012. The Company has no Level 3 financial assets or liabilities.








12


INTERNATIONAL GOLD CORP.





CONDENSED NOTES TO INTERIM FINANCIAL STATEMENTS





FOR THE SIX MONTHS ENDED JUNE 30, 2012 AND 2011


(Unaudited)


(Stated in U.S. Dollars)








8.
SUBSEQUENT EVENTS





In addition to the subsequent capital stock transactions disclosed in Note 3, on July 15, 2012, the Company entered into a Letter of Intent (the “LOI”) with SignalChem Lifesciences Corporation, a private company incorporated in the Province of British Columbia, Canada (“SLC”), with respect to the proposed exchange of all of the issued and outstanding shares of SLC. Pursuant to the terms of the LOI, as consideration for the acquisition of all of the issued and outstanding securities of SLC, the Company agreed to issue 40,000,000 shares of its common stock to the SLC shareholders. Closing of the transaction is subject to a number of conditions including: satisfactory completion of due diligence by both parties; obtaining all necessary governmental, regulatory and third party consents, waivers and approvals; and completion of an interim financing with proceeds intended to be used to fund working capital of the Company. There is no assurance that the transaction will be completed as planned or at all.





Management has evaluated subsequent events and the impact on the reported results and disclosures and has concluded that no other significant events require disclosure as of the date these financial statements were issued.
























































13





ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS





This section of this report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions.





Plan of Operation





We are currently considered a “shell” company inasmuch as we are not generating revenues, do not own an operating business, and have no specific plan other than to engage in a merger or acquisition transaction with an  operating company or business. We have no employees and minimal cash.





Our plan is to seek, investigate, and consummate a merger or other business combination, purchase of assets or other strategic transaction with a corporation, partnership, or other operating business entity desiring the perceived advantages of becoming a publicly reporting and publicly held corporation. We have no operating business, and conduct minimal operations necessary to meet regulatory requirements. Our ability to commence any operations is contingent upon obtaining adequate financial resources.





We may consider a business which has recently commenced operations and is seeking to develop a new product or service, or a business combination may involve the acquisition of, or merger with, a company which does not need substantial additional capital, but which desires to establish a public trading market for its shares, while avoiding, among other things, the time delays, significant expense, and loss of voting control which may occur in a public offering. Alternatively, we may consider acquiring a project that is no longer aligned with the strategic direction of the business in which it was developed.





We are not currently engaged in any business activities that provide cash flow. The costs of meeting our regulatory and reporting requirements, as well as the costs of investigating and analyzing potential business combinations or projects for the next twelve months will need to be funded through sales of our common stock and/or loans.





Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue as an on-going business for the next twelve months unless we obtain additional capital to pay our bills. We have not generated any revenues and no revenues are anticipated until after we engage in a merger or acquisition transaction. We can not currently estimate the timing of any possible future revenues. We currently have no definitive agreements or understandings with any prospective business combination or project candidates and there are no assurances that we will find a suitable business with which to combine or project to acquire. The implementation of our business objectives is wholly contingent upon a business combination or project acquisition and/or the successful sale of our securities. We intend to utilize the proceeds of any offering, any sales of equity securities or debt securities, bank and other borrowings or a combination of those sources to effect a business combination or project acquisition which we believe has significant growth potential. There is no certainty that we will be able to complete any of those steps. Our only sources for cash at this time are loans, or investments by others in a public offering or a private placement.





We have no employees. The services of our president and CEO, Robert M. Baker, are provided through a consulting agreement effective January1, 2012 with a company owned by Mr. Baker. We expect to use outside consultants, advisors, attorneys and accountants as necessary, none of whom will be hired on a retainer basis. We do not anticipate hiring any full-time employees so long as we are seeking and evaluating business opportunities.





The time and costs required to select and evaluate a target business or project (including conducting a due diligence review) and to structure and consummate the business combination or project acquisition (including negotiating and documenting relevant agreements and preparing requisite documents for filing pursuant to applicable corporate and securities laws) cannot be determined at this time. Our president will devote such time as he deems reasonably necessary to carry out our business and affairs. The amount of time devoted to our business and affairs may vary significantly depending upon, among other things, whether we have identified a target business or project or are engaged in active negotiation of a business combination or project acquisition.





We anticipate that various prospective target businesses or projects will be brought to our attention from various sources, including securities broker-dealers, investment bankers, venture capitalists, bankers and other members of the financial community.






14








ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)





Proposed Business Acquisition





On July 15, 2012, we entered into a Letter of Intent (the “LOI”) with SignalChem Lifesciences Corporation, a private company incorporated in the Province of British Columbia, Canada (“SLC”), with respect to the proposed exchange of all of the issued and outstanding shares of SLC.





Pursuant to the terms of the LOI, as consideration for the acquisition of all of the issued and outstanding securities of SLC, we agreed to issue 40,000,000 shares of our common stock to the SLC shareholders. Closing of the transaction is subject to a number of conditions including: satisfactory completion of due diligence by both parties; obtaining all necessary governmental, regulatory and third party consents, waivers and approvals; and completion of an interim financing with proceeds intended to be used to fund our working capital. There is no assurance that the transaction will be completed as planned or at all.





Forward-Looking Statements





The following summary regarding SLC contains "forward-looking statements". Those statements include, but are not limited to, statements with respect to SLC’s expected costs and timing for the further development and operation of its projects, efficacy of product candidates, proposed timelines, co-development and licensing of product candidates with third parties and projected milestones. In some cases, you can identify these statements by forward-looking words such as "may," "might," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue," the negative of these terms and other comparable terminology.





All forward-looking statements speak only as of the date on which they are made. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions concerning future events that are difficult to predict. Therefore, actual future events or results may differ materially from these statements.





The risks and uncertainties may cause SLC’s actual future results to be materially different than those expressed in SLC’s forward-looking statements. SLC cautions you not to place undue reliance on these forward-looking statements. SLC does not undertake any obligation to make any revisions to these forward-looking statements to reflect events or circumstances after the date of this Executive Summary or to reflect the occurrence of unanticipated events, except as required by law.





SLC Overview





SLC discovers and develops innovative, novel, small molecule targeted therapies for the treatment of cancer, inflammation/autoimmune and central nervous system diseases with unmet medical need.  SLC currently has created a robust pipeline of novel drug candidates for the treatment of cancer, inflammation/autoimmune and Parkinson/Alzheimer’s disease by applying its proprietary drug discovery technology platform.  SLC plans to begin human clinical trials with its first novel drug candidate SLC-0111 for cancer in 2013. In addition, SLC has developed and optimized a robust kinase technology platform that it believes will generate additional new drug candidates against clinically relevant and biologically validated next generation kinase targets. These new kinase drug candidates should significantly bolster the current drug candidate pipeline.





Kinases are currently among the most sought after drug targets as targeted therapies for new drug development in combating various diseases. Since 2000, with the successful product launches of the first generation kinase drugs such as Gleevec (Novartis), Tarceva (Genentech/Roche), and Iressa (AstraZeneca), new drug candidates that target kinases have the highest rate of innovation of any therapeutic target family. As of April 2012, there are a total of 14 kinase inhibitor products approved by FDA, all for the treatment of cancer.





The kinase targets are being aggressively pursued for therapeutic intervention because there are 518 protein kinases in the human genome and defects in these signaling enzymes account for more than 400 human diseases. All of the 14 FDA approved drugs on the market target or affect one or more of only about 11 kinase drug targets. Therefore there are potentially hundreds of unexploited next generation kinase targets that SLC can use for the design of novel and innovative targeted therapies. SLC is focused on producing novel and innovative drug candidates that target the next generation of kinases for the treatment of various human diseases.





SLC has assembled a fully integrated Kinase Drug Development Platform that is discovering and designing novel drug candidates against the next generation kinase targets to treat a variety of human diseases. SLC has produced more than 400 functionally active kinase enzymes that it seeks to employ to design and perform the optimal functional assays of cell signaling networks. SLC believes that it has established and validated optimal functional assay for the 400 active kinase targets. In addition, a kinase focused small molecule library, KineCoreTM, which incorporates features of drug like molecules has been assembled in-house and has been used in the high throughput screening process to generate hits against key validated and clinically relevant kinase targets. SLC believes that all these components provide it with a highly competitive advantage compared with other developers of kinase targeted therapies. SLC also believes that it is better positioned to assess drug molecules: for on-target and off-target effects, for their impact on cell signaling pathways, and for their impact on the broader signaling network. This information empowers SLC to design drugs that it believes are more effective, more selective, and less toxic against kinase targets than other drug developers who do not have access to this quality and breadth of targets and assays. In this way, SLC addresses the growing market demand within and upon the pharmaceutical drug development industry for personalized medicines and targeted therapies.








15




ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)





SLC’s Bioreagent Business





The bioreagent business arm of SLC is quickly growing in the life science signal transduction reagents space. SLC’s bioreagent business has continually expanded its products offering and achieved its projected growth year-over-year. Because of its unique expertise, the bioreagent business has become a substantial supplier of active enzymes and signaling proteins. SLC is commercializing and distributing these signaling products worldwide directly, through distributors and through corporate partnerships.





Since its inception, SLC’s bioreagent business has developed and optimized the necessary expertise to produce functionally active and highly pure recombinant forms of signaling enzymes; these include protein kinases, protein phosphatases, phosphodiesterases, transcriptional factors, histone deacetylases and methyltransferases. These products are utilized by scientists to identify new drug candidates, to validate targets and to study protein function. To maximize the value of these products and its offering, SLC’s bioreagent business continues to focus on adding complementary products to its offering. In addition, the company utilizes these products for its high throughput screening process in order to identify potent and selective drug candidates.





The discipline of signal transduction, which is defined as the flow of information within each of the body’s hundred trillion cells, has experienced explosive growth in the last two decades. The need for signaling enzyme and protein products and discovery services by the pharmaceutical and academic communities to study, understand, and exploit signal transduction processes has created an enormously lucrative business opportunity. SLC expects that the worldwide market for research reagents to significantly increase with the near term with industry fuelling this growth. Targets such as protein kinases, protein phosphatases, phosphodiesterases, transcriptional factors, histone deacetylases and methyltransferases amongst others are being pursued for therapeutic intervention with many new clinical candidates in development putting providers of biologically active enzymes and drug screening services in a unique growth position.





SLC’s advantage over its competitors arises from the 50 years of combined experience of its founders, management and scientists who have leveraged this expertise to develop an extensive line of research products. The vast wealth of experience has placed the Company at the forefront of signal transduction research and has allowed it to produce a large variety of signaling enzymes and proteins in their functionality active state.





As of 2010, SLC’s bioreagent business has operated with a positive cash flow and this aspect of the business is currently focused on expanding its revenue base.





SLC Capabilities and Resources





SignalChem Lifesciences Corporation is a Canadian company incorporated under the British Columbia Corporations Act with its principal office at 550-5600 Parkwood Way Richmond BC, V6V 2M2.





SLC’s principal office provides 6600 sq. ft. of office and wet lab space for performing biological assays, screening for drug candidates and testing for efficacy in various disease models. The company has a dedicated team of highly experienced employees and conscientiously manages its costs and cash flow through efficient management of technical resources, project planning, strategic alliances, and service contracts.





SLC has a strategic alliance with Advinus Therapeutics Inc., a TATA Enterprise, whereby Advinus will collaborate with SLC to cost effectively develop SLC’s novel drug candidates in a timely manner. Under the terms of the alliance, Advinus will provide chemistry and pharmaceutical development capabilities to SLC on these kinase programs in exchange for a share of the revenues during out-licensing of those programs. The Advinus site in Bangalore is over 240,000 sq. ft of modern laboratory and office space and provides extensive pharmaceutical development capabilities of toxicology, pharmacokinetics, process chemistry and analytical chemistry while the site in Pune is over 70,000 sq. ft and provides extensive drug discovery capabilities of medicinal chemistry, ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicology) optimization and in vivo pharmacology.





SLC has a service agreement with the British Columbia Cancer Agency in Vancouver to access expertise and resources in cancer biology such as specialized cancer animal models in addition to human clinical trials in exchange for approximately $90,000 per year. Services under this agreement are only provided at SLC’s request, and no payments are required if no services are provided. SLC also intends to enter into a service agreements with University of Florence to provide expertise and resources in medicinal chemistry drug design and synthesis and TC Scientific Inc in Edmonton to provide services in chemical synthesis in exchange for approximately $90,000 per year. Services under this agreement would only be provided at SLC’s request, and no payments would be required if no services were provided.






16




ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)




SLC Directors and Management Team





Zahir Popat – Chairman and Chief Executive Officer/Corporate Director – is an accomplished business professional with expertise constructing and managing successful lifesciences corporate alliances, and business relationships on five continents for more than 30 years.  Zahir Popat brings to SLC the expertise to structure and manage the company to attain a global presence through the power of knowledge and strategic partnerships by providing a network of global alliances that complement SLC’s in-house and international drug development capabilities.





Dr. Jasbinder Sanghera, Ph.D. – President and Chief Scientific Officer/Corporate Director –- is a serial entrepreneur with 22 years of experience in drug discovery, protein kinases, signal transduction and cancer research. Dr. Sanghera has led teams that advanced three small molecule candidates from discovery into human clinical trials.  He is the author of more than 80 research articles in peer-reviewed scientific journals and holds a number of patents. He co-founded and served as VP Drug Discovery of Kinetek Pharmaceuticals, Inc. from 1992 until its acquisition by QLT Inc. in 2004.  He then co-founded SignalChem Pharmaceuticals Inc and has built it into a profitable privately held business, that is a leader in the supply of cell signaling bioreagents for drug discovery and research.  Dr. Sanghera’s vision and goal for SLC is to target kinase cell signaling enzymes to create innovative targeted drug products for the treatment of the right disease in the right patient.





Jun Yan – Director, Biology – is an expert in target discovery and validation, signal transduction, and cancer biology. He is a co-founder of SignalChem Pharmaceuticals Inc. and MetaSignal Therapeutics Inc.  Jun Yan brings to SLC kinase biology expertise to produce and exploit novel protein kinases and cell signaling pathways as drug targets through the production of signal transduction proteins and design of optimal assay systems. Jun Yan also has extensive experience in high throughput screening process for the discovery of hits against validated enzyme targets.





Dr. Zaihui Zhang, Ph.D.  – Director, Medicinal Chemistry – has over 20 years of experience in medicinal chemistry, drug discovery and development, protein kinases and cancer research.   Dr. Zhang made major contributions to advancing three small molecules from discovery stage to clinical trial stage. He has co-authored more than 30 research papers and named co-inventor of more than 50 patents and patent applications. Dr. Zhang has managed several programs that have been successfully acquired by or partnered with top tier multinational pharmaceutical companies and biotech companies when he held the position of Director or Associate Director of Medicinal Chemistry of Xenon Pharmaceuticals, Active Pass, and Kinetek Pharmaceuticals. He brings to SLC expertise in all stages of drug discovery including hit-to-lead, lead optimization and preclinical development; project management and leadership; and intellectual property.





Kevin McDuffie – Director, Business Development – is an accomplished business professional with more than 25 years of business development, technology licensing, plus sales and marketing experience in the biotechnology, life science, and biomedical device markets. Kevin McDuffie brings to SLC expertise in structuring, implementing, and managing multiple partnerships, alliances, and technology licenses for drug development.





Dr. Shoukat Dedhar Ph.D. – Director, Cancer Biology – is a world expert in cancer biology and cell adhesion mechanisms and signal transduction with expertise in in vivo models of invasion and metastasis. With more than 30 years of experience in cancer research, Dr. Dedhar has authored more than 170 publications in the cancer field and holds a number of patents. His projects have received significant funding from CIHR, CBRCA, and CCSRI. Dr. Dedhar is the discoverer of Integrin Linked Kinase (ILK), a major target for cancer, cardiovascular disease and inflammation. He is also the discoverer of the enzyme target, CAIX, used in SLC’s hypoxia anticancer drug development program. He currently holds the position of Distinguished Scientist - Genetics Unit, Integrative Oncology at the BC Cancer Research Centre.





Dr. Claudiu Supuran Ph.D. – Director, Drug Design – is a world renowned medicinal chemist and has 22 years of research experience with projects financed by the EU and many private drug companies. He is a world expert on the chemistry of the hypoxia CAIX anticancer drug program inhibitors and activators. Dr. Supuran is co-author on more than 670 scientific publications and patents. He currently holds the position of Professor, Faculty of Pharmacy, Department of Chemistry, University of Florence.





Harvey Quan CMA – Director, Finance – has over 25 years of business and company operational experience. He has served as Senior Financial officer in many biotechnology companies and government funded institutes including Kinetek Pharmaceuticals Inc., Genome BC, Aquinox, and SignalChem. Harvey Quan brings to SLC expertise in financial operations management for drug development and biotechnology companies.






17








ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)





SLC’s Business Model





SLC’s business model is to generate novel drug candidates against biologically validated drug targets. Then SLC will actively partner with and license to biotechnology and pharmaceutical companies for later stage clinical development, to sustainably and significantly grow SLC’s revenue and its shareholder value.





The incentive for biotechnology and pharmaceutical drug development companies to partner with SLC is to develop the best quality targeted therapies to treat a variety of human diseases they deem important in a timely and cost effective manner by leveraging SLC’s robust, efficient, economical, and milestone driven Kinase Drug Development Platform. SLC provides the opportunity to develop the best quality targeted drug candidates from hit compound stage of development to Phase II ready clinical data package.





SLC intends to enter into product co-development partnerships with pharmaceutical and biotechnology companies to license intellectual property and drug development candidates. In the license transactions, SLC expects to receive payments in defined stages including 1) an upfront payment in cash or equity plus 2) one or more cash milestone payments when the drug achieves predetermined milestones in the development process, plus 3) royalties on sales of the future product or profit sharing relating to sales of the future product. The value of the payment terms will be negotiated based on several factors such as the stage of development of the drug candidate, intellectual property for the products, and the market opportunity for the proposed product.





Intellectual Property and Competitive Barriers to Entry





Patents on novel compositions of matter and pharmaceutical composition of innovative drug candidates, patents on the novel uses of these drug candidates as pharmaceutical compounds that treat the right disease in the right patient with the right drug, and patents on utilizing companion diagnostics based on the novel SLC assay tools are the primary barriers to entry for SLC’s competitors. SLC intends to obtain three patent applications for the CAIX hypoxia program that describe two proprietary classes of compounds that inhibit the CAIX enzyme target in hypoxic cancers and the concomitant biomarkers to identify the types of cancers that will be affected and to assess patient response to treatment with SLC’s drug products. SLC also intends to obtain a patent application covering the RSK2 for the treatment of triple negative breast cancers (TNBC).





There is also a technical barrier to entry exemplified by SLC’s extensive track record for being able to clone, express, purify, characterize, and develop functional screening assays for technically challenging kinase targets and other cell signaling proteins. This enables SLC to create better quality drug candidates for targeting functional activity of kinases within cell signaling pathways and signal transduction networks in terms of on-target and off-target effects; to select drug candidates with better toxicity profiles and pharmaceutical properties; and to perform better segmentation of the diseases (for example segmentation of the type of cancer by the cell signaling pathway signature of the cancer cells), leading to better selection criteria for responsive patients.





Limited Operating History; Need for Additional Capital





There is not sufficient historical financial information about us upon which to base an evaluation of our performance.  We are considered a shell company and have not generated any revenues from operations.  We cannot guarantee we will be successful in our business operations.  Our business is subject to risks inherent in the establishment of a new business enterprise, including, without limitation, the items listed in Item 1A RISK FACTORS in our report filed on Form 10-K for the year ended December 31, 2011.





We have no assurance that future financing will be available to us on acceptable terms.  If financing is not available on satisfactory terms, we may be unable to continue our operations.





18





ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)





Results of Operations





To June 30, 2012





The following summary of our results of operations should be read in conjunction with our financial statements for the period ended June 30, 2012 which are included with this Report.


Three Months Ended June 30

Change2012


2011

Amount

PercentageRevenue

$
-


$
-


$
-Operating Expenses


69,218



39,978



29,240Net (Loss)

$
(69,218
)

$
(39,978
)

$
(29,240
)


(73%)
 
 Six Months Ended June 30

Change2012


2011

Amount

PercentageRevenue

$
-


$
-


$
-Operating Expenses


124,191



54,078



70,113Net (Loss)

$
(124,191
)

$
(54,078
)

$
(70,113
)


130%


Revenues





We have had no operating revenues since our inception on December 9, 2004. We recorded a net loss of $69,218 for the three month period ended June 30, 2012 and have an accumulated deficit of $568,360. We have no way to generate any revenue until after we are able to effect a business combination or project acquisition. The possibility and timing of revenue being generated after that cannot be predicted at this time. While we have identified a proposed business acquisition (see discussion above re. SLC), there is no assurance that the transaction will be completed as planned or at all.





Expenses – Three month periods ended June 30, 2012 and 2011





Notable period over period differences are as follows:





Three Months Ended June


Change2012


2011


Amount


PercentageConsulting services

$
22,500


$
-


$
22,500



-Corporate support services

$
8,995


$
-


$
8,995



-Interest, bank and finance charges

$
4,805


$
10,746


$
(5,941
)


(55
%)Office, foreign exchange and sundry

$
(685
)

$
3,274


$
(3,959
)


(121
%)Professional fees

$
28,853


$
23,608


$
5,245



22
%Transfer and filing fees

$
4,750


$
2,350


$
2,400



102
%





§
Consulting services in the current period relate to fees for services of our president under the terms of a contract which commenced January 1, 2012.


§
In recognition of our constrained financial condition, the corporate support services provider agreed to forego regular monthly fees in the 2011 second quarter.


§
Interest, bank and finance charges were higher in 2011 primarily due the value of shares issued as additional consideration for a loan in 2011 being recorded as a finance charge, with no equivalent in 2012.


§
Office, foreign exchange and sundry decreased primarily due to a foreign exchange gain in the 2012 period, and a loss in the equivalent period in the prior year.


§
Professional fees increased primarily due to timing of invoicing for quarterly statement reviews.


§
Transfer and filing fees increased primarily due to the SEC’s new XBRL filing requirements in 2012.


19





ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)





Balance Sheet at June 30, 2012 and December 31, 2011





Items with notable period-end differences are as follows:





June 30


December 31


Change2012


2011


Amount


PercentageAmounts receivable

$
21,606


$
9,144


$
12,462



136
%Accounts payable and accrued liabilities

$
150,879


$
117,680


$
33,199



28
%Loans payable

$
94,652


$
112,289


$
(17,637
)


(16
%)Amounts due to related party

$
25,482


$
41,974


$
(16,492
)


(39
%)Shares to be issued

$
146,700


$
10,000


$
136,700



1,367
%





§
Amounts receivable increased due to the accrual of recoverable goods and services taxes in the current period.


§
Accounts payable and accrued liabilities increased mainly due to accrued accounting fees and related interest, plus accrued fees for corporate support services.


§
Loans payable decreased primarily due to a conversion of a loan into a subscription for shares, offset slightly by accrued interest on loan balances remaining.


§
Amounts due to related party decreased as a result of repayments made during the current period of loans from our president.


§
Shares to be issued increased due to receipt in the current quarter of amounts totaling $124,200, together with conversion of loans, as subscriptions for 2,734,000 shares of our common stock. Those shares were issued on July 24, 2012.




Liquidity and Capital Resources





As of June 30, 2012, our total assets were $21,711 and our total liabilities were $277,821. At that date we had cash of $105.





Our working capital as at June 30, 2012 and December 31, 2011 and the changes between those dates are summarized as follows:




June 30


December 31


Increase/(Decrease)2012


2011


Amount


PercentageCurrent Assets

$
21,711


$
9,903


$
11,808



119
%Current Liabilities


277,821



278,522



(701
)


-Working Capital (Deficiency)

$
(256,110
)

$
(268,619
)

$
12,509



(5
% )





The decrease in our working capital deficiency from December 31, 2011 to June 30, 2012 was primarily due to an increase in accrued recoverable goods and services taxes of approximately $12,000.




Cash Flows


Six Months Ended June 30


Increase/(Decrease)2012


2011


Amount


PercentageCash Flows (Used In) Provided By:Operating Activities

$
(98,362
)

$
(22,443
)

$
(75,919
)


338
%Investing Activities


-



(75,000
)


75,000



(100
%)Financing Activities


97,708



95,400



2,308



2
%Net increase (decrease) in cash

$
(654
)

$
(2,043
)

$
1,389



(68
% )




Cash Used In Operating Activities
 Operating expenses were higher by approximately $70,000 in the current six month period than in the equivalent period last year. This was primarily due to consulting services that were new this year of $45,000, increased corporate support services of approximately $11,000, and increased professional fees of approximately $15,000. Non-cash changes that impacted the net loss (i.e. changes in Amounts receivable,  Accounts payable, Accrued interest payable, Non-cash finance fees, and Loss on foreign exchange) increased year over year by approximately $6,000. As a result, the total change in cash used in operating activities was approximately $76,000.




20




ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)





Cash Used in Investing Activities


In 2011, we paid $75,000 as a deposit on a mineral property. There was no equivalent in the current six month period.





Cash Provided By Financing Activities


The minor increase in cash provided by financing activities was due to the receipt of subscriptions for our common stock being offset by net repayments of loans made by our president.





As of the date of this report, we have yet to generate any revenues from our business operations. Our ability to generate adequate amounts of cash to meet our needs is entirely dependent on the issuance of shares, debt securities, or loans.





Our principal source of working capital has been in the form of loans and capital contributions from our shareholders or management, loans from third parties, and funds received as subscriptions for our common stock. For the foreseeable future, we will have to continue to rely on those sources for funding. We have no assurance that we can successfully engage in any further private sales of our securities or that we can obtain any additional loans.








ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.





We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.








ITEM 4.
CONTROLS AND PROCEDURES.





Evaluation of Disclosure Controls and Procedures





We maintain “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. We conducted an evaluation under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report pursuant to Rule 13a-15 of the Exchange Act. Based on this Evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our Disclosure Controls were effective as of the end of the period covered by this report.





Changes in Internal Control Over Financial Reporting





There were no changes in our internal control over financial reporting during the quarter ended June 30, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.








PART II - OTHER INFORMATION





ITEM 1A.
RISK FACTORS





We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide information under this item.  Our business is subject to risks inherent in the establishment of a new business enterprise, including, without limitation, the items listed in Item 1A RISK FACTORS in our report filed on Form 10-K for the year ended December 31, 2011.





21





ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.





We had the following sales of unregistered securities in the six months ended June 30, 2012 and subsequently, to the date of this report.





During the period ended June 30, 2012:


§
We received payments totaling $114,200 as subscriptions for 2,284,000 shares of our common stock.


§
Loans totaling $22,500 were converted to a subscription for 450,000 shares of our common stock.





In July, 2012:


§
We received payments totaling $15,000 as subscriptions for 300,000 shares of our common.


§
A portion of a loan and accrued interest totaling $6,000 was converted to a subscription for 120,000 shares of our common stock.





On July 24, 2012, we issued 3,354,000 restricted shares of our common stock in connection with the above subscriptions, as well as a subscription for another 200,000 shares received in July, 2011.





All of the shares are part of a private placement of securities to offshore subscribers pursuant to Regulation S of the Securities Act of 1933. The subscribers represented that they are not a US person, as defined in Regulation S. No compensation was or will be paid in connection with these subscriptions.





On August 9, 2012, the Company received $50,000 as a subscription for 250,000 shares of its common stock. The shares are part of a second private placement of securities to offshore subscribers pursuant to Regulation S of the Securities Act of 1933. The subscriber represented that they are not a US person, as defined in Regulation S. Those shares have not yet been issued.








ITEM 6.
EXHIBITS.





The following documents are included herein:





Exhibit No.
Document Description31.1
Certification of Principal Executive and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.32.1
Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for the Chief Executive and Chief Financial Officer.














SIGNATURES





In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 17th day of August, 2012





INTERNATIONAL GOLD CORP.BY:
“Robert M. Baker”Robert M. BakerPresident, Principal Executive Officer, Treasurer, Principal Financial Officer, Principal Accounting Officer, and sole member of the Board of Directors











22





EXHIBIT INDEX








Exhibit No.
Document Description31.1
Certification of Principal Executive and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.32.1
Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for the Chief Executive and Chief Financial Officer.





































































23